

Day 1 - Wednesday, 20th March 2024

09:30 Registration opens

09:50 Introduction and welcome

Dr Channa Hewamadduma, consultant neurologist and honorary senior lecturer, Sheffield Teaching Hospitals NHS Foundation Trust

- Rationale for education
- What we hope to achieve through this upskill
- Standardise practice and reduce variance

Session 1 chair: Dr Channa Hewamadduma

10:00 Pathophysiology of myasthenia gravis and therapeutic targets

Prof Isabel Leite, associate professor and consultant neurologist, University of Oxford

- Pathophysiology of MG according to antibody status AChR-Ab or MuSK-Ab positive, and their impact in NMJ structure over time
- The key molecules and cells relevant to standard and current therapies in MG
- Relevant targets for immunotherapies used in recent and ongoing phase III clinical trials for MG

11:00 Ocular presentations of myasthenia

Dr Sithara Ramdas, consultant paediatric neurologist, University of Oxford

- Eliciting key clinical signs
- Pathology at ocular NMJ
- Pertinent differential diagnoses; CMS, MG & others
- Principles of management

12:00 Lunch & networking

Session 2 chair: Prof Isabel Leite

- 13:00 Diagnostic and key principles of management generalised myasthenia gravis Dr Maria Farrugia, consultant neurologist, NHS Greater Glasgow and Clyde
 - Seropositive
 - Seronegative
 - MuSK MG



14:00 Interactive case discussions Dr Maria Farrugia Prof Isabel Leite Prof Saiju Jacob, consultant neurologist, University Hospitals Birmingham NHS Foundation Trust

15:20 Refreshments

- 15:40 Patient perspective from a clinical view Chair: Dr Channa Hewamadduma Andrew Stephenson, expert patient
- 16:40 Reflections & final comments Dr Channa Hewamadduma Prof Saiju Jacob Prof Isabel Leite Dr Maria Farrugia
- 19:00 Pre dinner drinks
- 19:30 Informal dinner
- 21:00 Close of day 1



Day 2 - Thursday, 21st March 2024

08:15 Registration

Session 3 chair: Dr Channa Hewamadduma

08:30 Challenging cases Dr Maria Farrugia Prof Isabel Leite Prof Saiju Jacob

10:00 Refreshments

Session 4 chair: Dr Maria Farrugia

10:20 Rituximab/B-cell targeting therapies in myasthenia gravis

Dr John McConville, consultant neurologist, Belfast Health and Social Care Trust

- Role of B cells in the pathophysiology of MG
- CD19 targeted therapies Rituximab in MG/ why not fully effective
- Newer B-cell therapies

11:00 Novel therapies in myasthenia gravis: complement inhibitors

Dr Channa Hewamadduma

- Pathophysiology of complement in MG
- Complement inhibition as a novel therapeutic approach review of evidence
- How to prepare your clinic for C5 inhibitors
- Challenges in C5 use

11:30 Novel therapies: FcRn inhibitors

Dr Jennifer Spillane, consultant neurologist, Guy's and St Thomas' NHS Foundation Trust & University College London Hospitals NHS Foundation Trust

- FcRn blockers as a novel therapeutic approach
- Is your clinic prepared for FcRn inhibitors
- Challenges in FcRn use
- 12:00 Lunch

Session 5 chair: Prof Saiju Jacob

13:00 Myasthenia gravis in pregnancy

Dr Fiona Norwood, consultant neurologist, King's College London NHS Foundation Trust - Virtual

- Challenges in MG management in pregnancy
- Peripartum complications/advice
- Myasthenia in pregnancy: UK best practice guideline

This activity has been funded by sponsorship from Alexion Pharma UK Ltd, argenx UK Ltd and UCB Pharma Ltd. The sponsors have had no control over the organisation or educational content of this activity.



13:30 Myasthenia gravis in adolescence/transition

Dr Sithara Ramdas

- Natural history of childhood MG
- Management challenges in young people with MG
- How best to support
- Especially patients with sero -ve , neurophysiology -ve MG

14:00 Advising patients with MG - helping manage day to day life

Caroline Carmichael, myasthenia gravis nurse specialist, NHS Greater Glasgow and Clyde

- Supporting MG patients
- What specific aspects of MG specialist nurse is unique
- What advice will you give if someone is planning MG SpN service

14:30 Refreshments

Session 6 chairs: Prof Isabel Leite and Dr Maria Farrugia

15:00 Thymus gland and myasthenia gravis

Introduction and thymic pathology and neurology Prof Isabel Leite Surgical management of thymus Mr Alan Kirk, consultant thoracic surgeon, Golden Jubilee National Hospital, Glasgow Thymic oncology Dr David Gilligan, medical oncologist, Cambridge University Hospitals Discussion: Prof Leite, Mr Kirk and Dr Gilligan - Role of neurologist in the thymic MDT

16:15 Final remarks Dr Channa Hewamadduma

16:30 Meeting close & depart